Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Haematologica. 2023 Sep 28. doi: 10.3324/haematol.2023.283557. Online ahead of print.ABSTRACTFollicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma. Despite treatment advances that have improved outcomes for patients with relapsed or refractory (R/R) FL, many patients still die from progressive disease or treatment-related toxicities. In the phase Ib/II GO29365 study (NCT02257567), the safety and efficacy of polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) versus BR alone, and polatuzumab vedotin plus bendamustine and obinutuzumab (Pola-BG) as a single-arm cohort were evaluated in pa...
Source: Haematologica - September 28, 2023 Category: Hematology Authors: Christopher R Flowers Matthew J Matasar Alex F Herrera Mark Hertzberg Sarit Assouline Judit Demeter Andrew McMillan Amitkumar Mehta Stephen Opat Marek Trn ňný Lisa Musick Jamie Hirata Annie Yang Laurie H Sehn Source Type: research
Health-related quality of life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximab
CONCLUSIONS: During the first 24 weeks of treatment, zanubrutinib was associated with better HRQoL outcomes in patients with treatment-naive CLL/SLL without del(17p) compared to BR.PMID:37752878 | DOI:10.1080/03007995.2023.2262381 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - September 27, 2023 Category: Research Authors: Paolo Ghia Gisoo Barnes Keri Yang Constantine S Tam Tadeusz Robak Jennifer R Brown Brad S Kahl Tian Tian Andy Szeto Jason C Paik Mazyar Shadman Source Type: research
Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
ConclusionsPV therapy may be a relatively safe treatment method for DLBCL patients on HD. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - September 26, 2023 Category: Cancer & Oncology Source Type: research
BR vs. R ‑miniCHOP in unfit patients with B‑cell non‑Hodgkin lymphoma: A randomized, two‑center, cohort study
The objective remission rate (ORR) and adverse reactions were evaluated between the two groups. A total of 35 patients, recruited between January 2020 and December 2021, were included in this prospective study. The median age was 74 years (range, 70-82 years). The ORR in the BR group was similar to that in the R-miniCHOP group (73.3 vs. 75.0%; P=0.606). However, the BR group exhibited a lower incidence of leukopenia than the R-miniCHOP group (20.0 vs. 60.0%; P=0.037). The univariate analysis revealed that the ORR was influenced by the serum β2 microglobulin level. The BR regimen showed equivalent efficacy but more improve...
Source: Oncology Letters - September 4, 2023 Category: Cancer & Oncology Authors: Dongdong Zhang Yong Lin Youhong Dong Liling Zhang Source Type: research
Prolonged SARS ‐CoV‐2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report
We report a case of prolonged SARS-CoV-2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma. Four years previously, the patient had been diagnosed with follicular lymphoma (Stage IIIA, Grade 2). She received several chemotherapy regimens, including rituximab and radiation therapy. Although these therapies achieved complete response temporally, they did not continue and recurred at 8 months before. Obinutuzumab and bendamustine therapy was selected, and she received five courses of obinutuzumab and bendamustine. She also received a SARS-CoV-2 mRNA vaccine two times. Although she did not have...
Source: Clinical Case Reports - August 29, 2023 Category: General Medicine Authors: Ryosuke Kambe,
Masamichi Sato,
Daisuke Uehara,
Yutaka Iizuka,
Satoru Kakizaki Tags: CASE REPORT Source Type: research
Correction to: RE ‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
(Source: Annals of Hematology)
Source: Annals of Hematology - August 23, 2023 Category: Hematology Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
CONCLUSIONS: Assuming the uncertainty associated with the adjusted indirect comparison, zanubrutinib could be considered equivalent in efficacy to ibrutinib, however, the presence of differentiating safety features precludes assigning the two alternatives as equivalent therapeutic alternatives.PMID:37612185 | DOI:10.1016/j.farma.2023.07.006 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - August 23, 2023 Category: Drugs & Pharmacology Authors: Francisco Javier Salmer ón-Navas Ester Mar ía Barreiro-Fernández Silvia F énix-Caballero Source Type: research
